BRPI0923349A2 - Combinação antitumoral que associa o ave8062 e o docetaxel. - Google Patents

Combinação antitumoral que associa o ave8062 e o docetaxel.

Info

Publication number: BRPI0923349A2
Authority: BR; Brazil
Prior art keywords: ave8062; docetaxel; combination combining; antitumor combination; antitumor
Prior art date: 2008-12-12

Application number

BRPI0923349-0A

Other languages

English (en)

Inventor

Michèle Besenval

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-12

Filing date

2009-12-10

Publication date

2015-07-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923349(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-10 Application filed by Sanofi Sa filed Critical Sanofi Sa

2015-07-21 Publication of BRPI0923349A2 publication Critical patent/BRPI0923349A2/pt

Links

ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title 1
230000000259 anti-tumor effect Effects 0.000 title 1
229960003668 docetaxel Drugs 0.000 title 1
IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 title 1
229950003600 ombrabulin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BRPI0923349-0A 2008-12-12 2009-12-10 Combinação antitumoral que associa o ave8062 e o docetaxel. BRPI0923349A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0806979A FR2939665B1 (fr)	2008-12-12	2008-12-12	Combinaison antitumorale associant l'ave8062a et le docetaxel
PCT/FR2009/052475 WO2010067027A1 (fr)	2008-12-12	2009-12-10	Combinaison antitumorale associant l'ave8062 et le docetaxel

Publications (1)

Publication Number	Publication Date
BRPI0923349A2 true BRPI0923349A2 (pt)	2015-07-21

Family

ID=40790630

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0923349-0A BRPI0923349A2 (pt)	2008-12-12	2009-12-10	Combinação antitumoral que associa o ave8062 e o docetaxel.

Country Status (27)

Country	Link
US (1)	US20120004294A1 (pt)
EP (1)	EP2376076A1 (pt)
JP (1)	JP2012511554A (pt)
KR (1)	KR20110104932A (pt)
CN (1)	CN102245175A (pt)
AR (1)	AR074599A1 (pt)
AU (1)	AU2009326220A1 (pt)
BR (1)	BRPI0923349A2 (pt)
CA (1)	CA2746475A1 (pt)
CL (1)	CL2011001316A1 (pt)
CO (1)	CO6390037A2 (pt)
CR (1)	CR20110319A (pt)
EA (1)	EA201170803A1 (pt)
EC (1)	ECSP11011112A (pt)
FR (1)	FR2939665B1 (pt)
IL (1)	IL213458A0 (pt)
MA (1)	MA32955B1 (pt)
MX (1)	MX2011006253A (pt)
NI (1)	NI201100114A (pt)
PA (1)	PA8853301A1 (pt)
PE (1)	PE20120125A1 (pt)
SG (1)	SG172071A1 (pt)
TN (1)	TN2011000268A1 (pt)
TW (1)	TW201032798A (pt)
UY (1)	UY32318A (pt)
WO (1)	WO2010067027A1 (pt)
ZA (1)	ZA201104358B (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601676B1 (fr)	1986-07-17	1988-09-23	Rhone Poulenc Sante	Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr)	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es)	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US20050209310A1 (en)	2000-12-22	2005-09-22	Chaplin David J	Methods for modulating tumor growth and metastasis
WO2002056692A1 (en)	2000-12-22	2002-07-25	Bristol-Myers Squibb Company	Methods for modulating tumor growth and metastasis
US20020183266A1 (en) *	2001-03-15	2002-12-05	Aventis Pharma, S.A.	Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr)	2002-04-11	2004-06-04	Aventis Pharma Sa	Procedes de preparation de combretastatines

2008
- 2008-12-12 FR FR0806979A patent/FR2939665B1/fr not_active Expired - Fee Related
2009
- 2009-12-10 PE PE2011001197A patent/PE20120125A1/es not_active Application Discontinuation
- 2009-12-10 JP JP2011540175A patent/JP2012511554A/ja active Pending
- 2009-12-10 CN CN2009801497729A patent/CN102245175A/zh active Pending
- 2009-12-10 MA MA34002A patent/MA32955B1/fr unknown
- 2009-12-10 CA CA2746475A patent/CA2746475A1/fr not_active Abandoned
- 2009-12-10 WO PCT/FR2009/052475 patent/WO2010067027A1/fr not_active Ceased
- 2009-12-10 TW TW098142340A patent/TW201032798A/zh unknown
- 2009-12-10 BR BRPI0923349-0A patent/BRPI0923349A2/pt not_active IP Right Cessation
- 2009-12-10 MX MX2011006253A patent/MX2011006253A/es not_active Application Discontinuation
- 2009-12-10 EP EP09802160A patent/EP2376076A1/fr not_active Withdrawn
- 2009-12-10 EA EA201170803A patent/EA201170803A1/ru unknown
- 2009-12-10 AU AU2009326220A patent/AU2009326220A1/en not_active Abandoned
- 2009-12-10 SG SG2011042348A patent/SG172071A1/en unknown
- 2009-12-10 KR KR1020117013250A patent/KR20110104932A/ko not_active Withdrawn
- 2009-12-11 UY UY0001032318A patent/UY32318A/es not_active Application Discontinuation
- 2009-12-11 AR ARP090104814A patent/AR074599A1/es not_active Application Discontinuation
- 2009-12-11 PA PA20098853301A patent/PA8853301A1/es unknown
2011
- 2011-05-24 TN TN2011000268A patent/TN2011000268A1/fr unknown
- 2011-06-02 CL CL2011001316A patent/CL2011001316A1/es unknown
- 2011-06-06 US US13/153,975 patent/US20120004294A1/en not_active Abandoned
- 2011-06-07 EC EC2011011112A patent/ECSP11011112A/es unknown
- 2011-06-08 NI NI201100114A patent/NI201100114A/es unknown
- 2011-06-08 CR CR20110319A patent/CR20110319A/es unknown
- 2011-06-09 IL IL213458A patent/IL213458A0/en unknown
- 2011-06-10 CO CO11072133A patent/CO6390037A2/es not_active Application Discontinuation
- 2011-06-10 ZA ZA2011/04358A patent/ZA201104358B/en unknown

Also Published As

Publication number	Publication date
CL2011001316A1 (es)	2011-10-28
FR2939665B1 (fr)	2011-10-07
KR20110104932A (ko)	2011-09-23
PA8853301A1 (es)	2010-07-27
TN2011000268A1 (fr)	2012-12-17
ECSP11011112A (es)	2011-07-29
JP2012511554A (ja)	2012-05-24
TW201032798A (en)	2010-09-16
EP2376076A1 (fr)	2011-10-19
US20120004294A1 (en)	2012-01-05
SG172071A1 (en)	2011-07-28
CR20110319A (es)	2011-09-20
WO2010067027A1 (fr)	2010-06-17
IL213458A0 (en)	2011-07-31
CA2746475A1 (fr)	2010-06-17
MA32955B1 (fr)	2012-01-02
CN102245175A (zh)	2011-11-16
UY32318A (es)	2010-07-30
AU2009326220A1 (en)	2011-07-07
AR074599A1 (es)	2011-01-26
ZA201104358B (en)	2012-09-26
CO6390037A2 (es)	2012-02-29
MX2011006253A (es)	2011-11-04
EA201170803A1 (ru)	2011-12-30
PE20120125A1 (es)	2012-02-23
FR2939665A1 (fr)	2010-06-18
NI201100114A (es)	2011-12-13

Legal Events

Date	Code	Title	Description
2015-08-25	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 5A ANUIDADE.
2016-05-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
EP2239264A4 (en)	2012-01-11	ANTITUMORAL MEDIUM
BRPI0920428A2 (pt)	2019-09-24	inalador.
BRPI0816896A2 (pt)	2015-03-24	Arranjo de diferencial e mancal
BRPI1008955A2 (pt)	2015-09-01	Terapia de combinação com derivados de tiocolchicina.
BRPI0922305A2 (pt)	2016-06-21	composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida
BRPI0922059A2 (pt)	2015-12-15	painel anti-ruído.
EP2341268A4 (en)	2013-09-25	GASKET
BR112012002877A2 (pt)	2017-02-14	dilatador e conjunto.
BRPI0910116A2 (pt)	2017-03-21	desvio transparente e mecanismos associados
EP2147122A4 (en)	2010-11-17	ENZYMATIC TUMOR THERAPY
BRPI0907448A2 (pt)	2015-07-14	Instrumentos.
BRPI1014197A2 (pt)	2016-04-26	combinação antitumoral que compreende o ave8062 e o sorafenib
BRPI1011827A2 (pt)	2016-03-22	combinação antitumoral, compreendendo cabazitaxel e a capecitabina
AU325331S (en)	2009-03-24	Fan
BRPI0813187A2 (pt)	2014-10-14	13-hidroperóxido liases modificadas e respectivos usos.
NL2003481A1 (nl)	2010-02-15	Improved LED arrangement and lamp assemblies.
ECSP12012343A (es)	2012-12-28	Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino
EP2348021A4 (en)	2012-03-21	ROTAXAN COMPOUND AND ANTITUMORANTS
FR2945589B1 (fr)	2015-08-07	Diffuseur.
IL213458A0 (en)	2011-07-31	Antitumor combination combining ave8062 and docetaxel
HK1162963A (en)	2012-09-07	Antitumor combination combining ave8062 and docetaxel
AU320051S (en)	2008-06-26	Centraliser segment
FI8194U1 (fi)	2009-02-27	Lehtiö ja lehtiön sisältävä ostosmuistikko
AU325097S (en)	2009-03-12	Lamp (AR111-1)
AU325096S (en)	2009-03-12	Lamp (par16 GU10-1)